TILT´s Head of R&D Riikka Havunen successfully defended her PhD thesis “Enhancing adoptive cell therapy of solid tumours with armed oncolytic adenoviruses” on 9th of November 2018. Riikka´s thesis describes the characterization and key preclinical results of TILT-123. Congratulations!
Please contact our business development team to meet us at the following events:
Location: Boston (MA, USA)